Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
169
mentions
- X 140
- News 22
- Blogs 3
- YouTube 2
- +1 more
Luis Paz-Ares
PubHawk tracks social media discussions for 3 articles by authors named Luis Paz-Ares.
Mentions
307
Peak: 108 in Feb 2022
across 3 tracked articles
Extended reach
1,458,368
potential audience
Total likes
541
Video views
477
Mentions per month
Sep 2012 – Jul 2025Where it's discussed
-
X / Twitter250 posts
-
News42 articles
-
YouTube4 videos
-
Facebook4 posts
-
Blogs4 articles
-
Reddit3 posts
Tracked by PubHawk
Most discussed articles
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
117
mentions
- X 95
- News 18
- Facebook 2
- YouTube 1
- +1 more
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
21
mentions
- X 15
- Reddit 3
- News 2
- YouTube 1
From PubMed
All publications
Searching PubMed…